Previous 10 | Next 10 |
Data by YCharts Acer Therapeutics Inc. ( ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company's focus is to acquire commercial or near-commercial stage orphan or ultra-orphan drugs to treat rare and ultra-rare diseases with critic...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the first quarter with additional terms of the purchase not disclosed. Horizo...
- Scott Brun, M.D. Named Senior R&D Advisor - Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external sea...
After market close on Tuesday, Irish drug company Horizon Therapeutics (NASDAQ: HZNP) received a nice surprise from the Food and Drug Administration (FDA). The company's drug Tepezza was approved earlier than expected. This is the first therapy that will hit the market for thyroid ...
-- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 ...
The Food and Drug Administration (FDA) announced on Tuesday that it had just approved the first-ever treatment for thyroid eye disease (TED), Tepezza, which is developed by Horizon Therapeutics (NASDAQ: HZNP) . Thyroid eye disease, also known as Graves' ophthalmopathy, is a rare disease that...
The FDA approves Horizon Therapeutics' ( HZNP -0.4% ) Tepezza (teprotumumab-trbw) for the treatment of thyroid eye disease, an Orphan Drug, Priority Review, Fast Track and Breakthrough Therapy indication. The agency's action date was March 8. More news on: Horizon Therapeutics Public L...
-- First and only FDA-approved medicine for TED, a serious, progressive, vision-threatening rare disease -- -- Clinical improvements were seen as early as six weeks, with continued improvement across the 24-week treatment period -- -- Approval comes ahead of the Prescription Drug ...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with this Read more ...
Based on encouraging sales to date, Horizon Therapeutics (NASDAQ: HZNP ) boosts its peak sales expectation for Krystexxa (pegloticase injection) to more than $1B from more than $750M. Sales growth in 2019 should be more than 25%. More news on: Horizon Therapeutics Public Limited Company,...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...